Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04401423 · ClinicalTrials.gov registry record · Phase 2
TXA127 for the Treatment of Severe COVID-19
A Phase 2 study, sponsored by Columbia University.
- Completed
- Registry status
- Phase 2
- Development phase
- 22
- Enrollment target
NCT04401423 is a Phase 2 study that has completed, run by Columbia University. The registered enrollment target is 22 participants.
The verdict
NCT04401423, a Phase 2 study, has completed, sponsored by Columbia University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 22 participants
- Enrollment target
Study Summary
The purpose of this study is to determine if administration of angiotensin-(1-7) (TXA127) prevents acute kidney injury and deterioration into multi-organ failure in patients with severe COVID-19. Participants will undergo a 10-day treatment with either placebo or study drug. The drug will be administered intravenously for 3 hours once each day for 10 days consecutively.
Interventions
- DRUG Placebo
- DRUG TXA127
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22 participants |
| Start Date | 2021-02-10 |
| Est. Completion | 2021-06-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04401423
The ClinicalTrials.gov registry entry for NCT04401423 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 22 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Columbia University, which has 958 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04401423 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04401423 about?
NCT04401423 is a clinical study titled "TXA127 for the Treatment of Severe COVID-19". The purpose of this study is to determine if administration of angiotensin-(1-7) (TXA127) prevents acute kidney injury and deterioration into multi-organ failure in patients with severe COVID-19. Participants will undergo a 10-day treatment with either placebo or study drug. The drug will be adminis...
What is the current status of trial NCT04401423?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 22 participants. The study started on 2021-02-10. Estimated completion is 2021-06-10.
What interventions are being tested in trial NCT04401423?
The interventions under investigation include: Placebo (DRUG), TXA127 (DRUG).
Who is sponsoring clinical trial NCT04401423?
This trial is sponsored by Columbia University, which has 958 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.